Navigation Links
ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Date:6/17/2008

d; "We are very pleased to enter this partnership with ThromboGenics and BioInvent. This novel antibody, TB-403 has the potential to play a major role in the treatment of cancer and we are committed to driving ahead with its development. In addition, we look forward to developing a strong working relationship with ThromboGenics and BioInvent."

Notes to Editors:

About TB-403

TB-403 was in-licensed by ThromboGenics from the Flanders Institute for Biotechnology (VIB) at the University of Leuven, Belgium, where the therapeutic potential of anti-PlGF agents to treat cancer was first developed in the laboratory of Prof. Peter Carmeliet.

Angiogenesis inhibitors such as TB-403 are therapeutic agents that work by blocking the development of new blood vessels, thereby depriving growing cancer tumour cells of oxygen and nutrients. This approach in turn is thought to stop the tumour from growing and spreading to other parts of the body. PlGF is a homologue of VEGF and current preclinical evidence suggests that it may not affect normal, physiological angiogenesis and is predominantly involved in angiogenesis of malignant tissue.

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF). ThromboGenics and BioInvent have recently signed a license agreement with Roche for TB-403 worth EUR 500 million plus royalties. TB-403 is scheduled to enter a Phase Ib clinical t
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... 20, 2015 The global genotyping market ... during the forecast period of 2015 to 2020 to ... used in drug discovery and development process and to ... In addition to this,heavy investments by key manufacturers to ... also propelling market growth. Browse 113 market data tables ...
(Date:5/20/2015)... 2015  Marc Tessier-Lavigne, president of The Rockefeller ... million from The Marie-Josée and Henry R. Kravis ... that will be the centerpiece of the University,s ... R. Kravis Research Building, two stories high, will ... three city blocks following the shoreline of the ...
(Date:5/20/2015)...  Resolution Bioscience announced today the successful results from ... , a blood-based liquid biopsy for an ALK-gene fusion driver ... most common form of this cancer. Researchers or clinicians ... personalized therapies and direct them into clinical trials with ... Health, the CLIA authority in Washington State ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 ... transporter assay services for Drug-Drug Interactions (DDI), Metabolism ... Pharma, a world leader in assessing impact of ... Systems Pharmacology supported by biosimulation, announced today that ... agreement allows both companies to expand their product ...
Breaking Biology Technology:Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 2The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 3The Marie-Josee and Henry R. Kravis Foundation Provides Landmark Gift of $100 Million to The Rockefeller University 4Resolution Bioscience Receives CLIA Certification for its Diagnostic Laboratory and Launches CLIA-Certified Liquid Biopsy for Lung Cancer 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 2Optivia Biotechnology Inc. and Rhenovia Pharma Sign Partnership Agreement 3
... Toronto Stock Exchange Symbol: MS, EDMONTON, Nov. ... leading developer in the treatment of multiple sclerosis ... been enrolled in its MAESTRO-03,U.S. pivotal phase III ... progressive multiple sclerosis (SPMS). An interim safety and,efficacy ...
... Alma Lasers Ltd., a global,leader in the development ... systems, today announced that it has,been named Israel,s ... 50 program. The program is presented by Deloitte ... growth over five years from,2002-2006. Howard Kelly, ...
... Associated with Chronic Pain Conditions in Patients Who ... ... FRAZER, Pa., Nov. 12 Cephalon, Inc. (Nasdaq:,CEPH) today announced ... Food and Drug Administration (FDA) seeking approval to,market FENTORA(R) (fentanyl buccal ...
Cached Biology Technology:BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial 2BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial 3Alma Lasers Ranked 9th in Deloitte Technology Fast 50 Award 2Cephalon Submits Supplemental New Drug Application for FENTORA 2Cephalon Submits Supplemental New Drug Application for FENTORA 3Cephalon Submits Supplemental New Drug Application for FENTORA 4Cephalon Submits Supplemental New Drug Application for FENTORA 5Cephalon Submits Supplemental New Drug Application for FENTORA 6Cephalon Submits Supplemental New Drug Application for FENTORA 7
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... mankind and the environment, there is a growing ... and education that new, more integrative approaches to ... multidisciplinary approaches to solving problems at the frontiers ... institutional level. , Integrated Science − New Approaches ...
... Actor and pancreatic cancer patient Patrick Swayze,s recent hospitalization ... system underscores the sensitivity of the lungs: many patients ... the disease itself. Lungs are delicate and exposed ... the body has developed an elaborate immuno-defense system to ...
... over the last few decades in old-growth forests of the ... worrisome trend is regional warming, according to a U.S. Geological ... 23. The study found that the increase in dying ... a wide variety of forest types, at all elevations, in ...
Cached Biology News:Research elucidates way lungs fight bacteria and prevent infection 2Tree deaths have doubled across the western US 2
Dako Target Retrieval Solution, Citrate pH 6 (x 10) For more information, please visit Dako' web-site. EU regulatory status: CE US regulatory status: IVD...
... data acquisition interface. All the functionality of ... processor, increased memory and more available channels ... also inlcudes an option for programmable front-end ... 16 to 48 waveform inputs and from ...
... to off-white solid. Increases the expression of glutathione ... in H 2 O. Unstable in aqueous ... EK7713840, CAS 3211-76-5, M.W. 196.1. References: ... and Junod, A.F. 1995. Biochem. J. ...
... designed to provide a thin film-like barrier when a ... This barrier creates the proper surface tension to ... the slide. PAP Pen contains a special formulation ... can be removed, if desired, by xylene after the ...
Biology Products: